Recombinant Plasma Protein Therapeutics Market By Drug Class (Recombinant Factor VIII and Recombinant Factor IX), By Cell Line (Chinese Hamster Ovary, Baby Hamster Kidney and Human Embryonic Kidney and Other), By Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease and Other) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The recombinant plasma protein therapeutics market is set to grow from US$ 7,788.9 million in 2017 to US$ 15,910.5 million in 2026, expanding at an annual growth rate of 8.3% during the forecast period from 2018 to 2026. According to the World Federation of Hemophilia (WFH), approximately 1 in 1,000 people worldwide suffer from some form of a bleeding disorder, and 75% of them receive inadequate treatment or remain undiagnosed.

Market Synopsis

Recombinant coagulation factor VIII is becoming more popular in the treatment of hemophilia A due to its lack of bloodborne transmission disease and less severe side effects when compared to desmopressin.

Recombinant coagulation factor VIII is leading the drug class segment for the recombinant plasma protein therapeutics market. It is preferred over human plasma-derived products to avoid the potential transmission of bloodborne infections. It is replacing desmopressin in treating mild hemophilia due to its fewer adverse effects. Recombinant factor IX will gain growth momentum in the near future owing to the recent FDA approval of Rebinyn (Novo Nordisk) for the long-term treatment of hemophilia B.

The ability to adapt growth conditions in serum-free suspension, a powerful gene amplification system and the capacity for post-translational modification drive the Chinese hamster ovary cell lines in recombinant protein synthesis.

Over the last two decades, Chinese hamster ovarian cell lines have gained immense popularity over other cell lines, such as baby hamster kidney cell lines and human embryonic kidney cell lines. Its ability to adapt to serum-free suspension growth conditions, perform powerful gene amplifications, and undergo post-translational modification distinguishes it as the most demanding cell line in recombinant protein synthesis.

high prevalence rate, with 70% of diagnosed patients having a severe form of hemophilia, market growth

Hemophilia A, also known as clotting factor VIII deficiency or classical hemophilia, is currently leading the indication segment for the recombinant plasma protein therapeutics market. It has a high prevalence rate of 1 in 5000 people, with approximately 70% of diagnosed patients reported to be suffering from a severe form of hemophilia A.

The other type is hemophilia B, which is a less common form with an occurrence rate of 1 in 25,000 people and is caused by a lack of clotting factor IX. Von Willebrand disease is keen to register impressive growth in the near future due to its high occurrence in blood group O and rising public health awareness.

The rising prevalence of hemophilia A and the presence of a comprehensive network of federally funded treatment centers for hemophilia drive market growth in North America.

North America reigns over the regional segment of the recombinant plasma protein therapeutics market with a share of 40%. The chief factors controlling its market growth are the rising prevalence of hemophilia A. According to the research findings of the Centers for Disease Control and Prevention (CDC), approximately 20,000 people are suffering from hemophilia in the United States.

The existence of a comprehensive network of federally funded treatment centers for hemophilia caters to the medical needs of 70% of patients with blood clotting disorders in the North American region. Due to the increasing number of newborns with hemophilia, Europe accounts for 30% of the market share. According to European Medical Agency (EMA) research findings, 400 babies are born with hemophilia each year.

The presence of major players such as Novo Nordisk A/S, Bayer AG, Shire Plc, and others in Europe boosts the market growth. Asia Pacific holds 20% market growth and is keen to register rapid growth during the forecast period owing to the adoption of recombinant technology for protein synthesis and a large patient pool suffering from blood clotting disorders.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Recombinant plasma protein therapeutics market segmentation is as follows:

Biotechnology companies manufacturing recombinant plasma proteins are Aptevo Therapeutics, Bayer AG, Bioverativ Therapeutics, Inc., CSL Behring, Novo Nordisk A/S, Octapharma, Plc., Pfizer, Inc., Pharming Group NV, Shire, Plc., and Viropharma Biologics, Inc.

Key questions are answered in this report.

• Which biotechnology companies are manufacturing recombinant coagulation factors?
• Why are recombinant coagulation factors replacing human plasma-derived proteins and desmopressin in treating hemophilia A?
• What is the disease etiology and treatment regimen for Von Willebrand's disease?
• Which factors make the Chinese hamster ovary the most popular cell line in comparison to other cell lines?
• What will be the market trend in the developed and developing nations during the forecast period concerning the market growth of recombinant plasma protein therapeutics?

Frequently Asked Question: